Janet McGill, MD
Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1811915325
Payments from drug & device makers
Across 574 payments — averaging $1441.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$463K
- Dexcom, Inc.$66K
- Mannkind Corporation$42K
- Novo Nordisk AS$36K
- Lexicon Pharmaceuticals, Inc.$35K
- Novo Nordisk$29K
- plus $155K from 30 others
Across 25 payments — averaging $1062.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$23K
- Lexicon Pharmaceuticals, Inc.$2K
- Novo Nordisk AS$1K
- Gilead$1K
What the payments were for
- Consulting fees$91,27643%
- Speaking & faculty fees$62,62730%
- Travel & lodging$43,66621%
- Food & beverage$14,4627%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 38 | $463,337 |
| Dexcom, Inc. | 50 | $66,113 |
| Mannkind Corporation | 61 | $41,715 |
| Novo Nordisk AS | 158 | $36,264 |
| Lexicon Pharmaceuticals, Inc. | 6 | $35,406 |
| Novo Nordisk | 41 | $29,410 |
| Sanofi US Services Inc. | 7 | $29,173 |
| Bayer | 50 | $18,639 |
| Boehringer Ingelheim International GmbH | 2 | $16,441 |
| Boehringer Ingelheim | 9 | $13,997 |
| Lilly USA, LLC | 48 | $13,996 |
| Phadia AB | 2 | $13,782 |
| Pfizer | 3 | $7,730 |
| Aegerion Pharmaceuticals, Inc. | 14 | $7,586 |
| Eli Lilly | 12 | $7,525 |
| Gilead | 3 | $6,984 |
| Johnson & Johnson | 7 | $5,948 |
| Phadia US Inc. | 3 | $3,708 |
| Boehringer Ingelheim Mexico SA De CV | 1 | $2,000 |
| Novartis | 1 | $1,919 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $1,440 |
| Abbott | 25 | $1,283 |
| Sequel Med Tech, LLC | 9 | $687 |
| Alnylam Pharmaceuticals Inc. | 1 | $613 |
| BETA Bionics, Inc. | 4 | $477 |
| AstraZeneca | 5 | $336 |
| Insulet Corporation | 3 | $273 |
| Amgen | 2 | $199 |
| Sanofi-aventis U.S. LLC | 1 | $138 |
| Corcept Therapeutics | 1 | $116 |
| Tandem Diabetes Care, Inc. | 1 | $115 |
| Janssen Scientific Affairs, LLC | 1 | $114 |
| Ascendis Pharma Endocrinology Inc | 1 | $108 |
| Valeritas, Inc. | 1 | $36 |
| Senseonics, Incorporated | 1 | $31 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFREZZA$40,478
- Kerendia$17,057
- JARDIANCE$9,566
- DEXCOM G6 CGM SYSTEM$8,545
- Victoza$7,696
- MYALEPT$7,257
- DEXCOM CGM$6,602
- TRADJENTA$6,260
- INVOKANA$5,904
- Tresiba$5,531
- ImmunoCAP$3,708
- CYCLOSET$1,440
- iLet Bionic Pancreas$1,402
- MINIMED 780G$385
- TWIIST$384
- MOUNJARO$356
- DEXCOM G6 TRANSMITTER$288
- FreeStyle Libre 2$282
- Omnipod$238
- Non-Covered$188
How this compares
$827,656 in reported general payments places this provider in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 141 | $177,352 |
| OzempicSemaglutide | 104 | $159,970 |
| MounjaroTirzepatide | 133 | $153,176 |
| JardianceEmpagliflozin | 78 | $101,775 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 55 | $65,886 |
| FarxigaDapagliflozin Propanediol | 43 | $38,516 |
| NovologInsulin Aspart | 47 | $20,930 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $19,101 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $19,091 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 125 | $17,694 |
| KerendiaFinerenone | 16 | $15,878 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 31 | $14,012 |
| Humalog Kwikpen U-100Insulin Lispro | 53 | $13,016 |
| HumalogInsulin Lispro | 44 | $12,705 |
| Novolog FlexpenInsulin Aspart | 47 | $11,893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $13,996 | $344,949336 claims |
| Novo NordiskOzempic, Novolog | $29,410 | $180,899151 claims |
| Boehringer IngelheimJardiance | $13,997 | $101,77578 claims |
| AstraZenecaFarxiga | $336 | $38,51643 claims |
| BayerKerendia | $18,639 | $15,87816 claims |
| Johnson & JohnsonInvokana | $5,948 | $11,24414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Louis
- Thomas NickolasSaint Louis$945K
- Anne GoldbergSaint Louis$830K
- Julie SilversteinSaint Louis$536K
- Sandeep DhindsaSaint Louis$173K
- Maamoun SalamSaint Louis$170K
- Michael WhyteSaint Louis$133K
- Fumihiko UranoSaint Louis$122K
- Farid RomanSaint Louis$62K
- Kathryn DiemerSaint Louis$57K
- Bharathi RajuSaint Louis$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.